Clinical trial
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
NCT03634982
Study timeline
Study start (actual)2018-09-28Date precision: day
Registry last updated2022-09-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumorsunresolved
Interventions
RMC-4630DRUG
Sponsors & collaborators
Revolution Medicines, Inc.lead sponsor
Sanoficollaborator
Mapped research locations
BostonMassachusetts, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1TampaFlorida, United States1AuroraColorado, United States1Oklahoma CityOklahoma, United States1AustinTexas, United States1SacramentoCalifornia, United States1OrangeCalifornia, United States1ScottsdaleArizona, United States1DuarteCalifornia, United States1SarasotaFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03634982 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.